{"entity":{"id":"chisel","kind":"trial","name":"CHISEL (TROG 09.02)","aka":[],"tldr":"CHISEL is the randomised trial that proved stereotactic radiotherapy beats conventional radiotherapy for early lung cancer in patients who cannot have surgery, with better local control and longer survival.","summary":"CHISEL randomised 101 patients with peripheral stage I non-small-cell lung cancer unfit for surgery to stereotactic ablative radiotherapy (54 Gy in three or 48 Gy in four fractions) or conventional radiotherapy (66 Gy in 33 or 50 Gy in 20). Local failure was less frequent with stereotactic treatment (hazard ratio 0.32) and overall survival was longer, median 5 years versus 3 years, with similar toxicity (Ball and colleagues, Lancet Oncology 2019).","status":"positive","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT01014130","url":"https://clinicaltrials.gov/study/NCT01014130"},{"label":"Lancet Oncology 2019","url":"https://doi.org/10.1016/S1470-2045(18)30896-9"}],"tags":["radiation-wave2"],"related":[],"cancers":["nsclc","resectable-nsclc"],"sections":[],"technologies":["sbrt","respiratory-motion-management"],"targets":[],"drugs":[],"companies":["trog"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-chisel-lancet-oncol-2019"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT01014130","phase":"3","setting":"Inoperable stage I non-small-cell lung cancer: stereotactic ablative radiotherapy versus conventionally fractionated radiotherapy","sponsor":"Trans-Tasman Radiation Oncology Group","result":"Local failure hazard ratio 0.32 favouring SABR; median overall survival 5 years vs 3 years.","started":"2009-12","startedType":"actual","yearReported":2019,"enrolled":101,"enrolledBasis":"registry","outcomes":[{"endpoint":"Local treatment failure (freedom from local failure was the primary endpoint)","primary":true,"unit":"%","arms":[{"name":"SABR","n":66,"value":14},{"name":"Standard radiotherapy","n":35,"value":31}],"hr":0.32,"ci":[0.13,0.77],"p":"0.0077","source":"https://doi.org/10.1016/S1470-2045(18)30896-9"}]},"route":"/trials/chisel/","neighbours":{"cancer":[{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"resectable-nsclc","kind":"cancer","name":"Resectable stage I to III non-small-cell lung cancer","route":"/cancers/resectable-nsclc/"}],"technology":[{"id":"respiratory-motion-management","kind":"technology","name":"Respiratory motion management (4D-CT, gating, breath-hold, tracking)","route":"/technologies/respiratory-motion-management/"},{"id":"sbrt","kind":"technology","name":"SBRT / SABR (stereotactic radiotherapy)","route":"/technologies/sbrt/"}],"company":[{"id":"trog","kind":"company","name":"TROG Cancer Research","route":"/companies/trog/"}],"paper":[{"id":"paper-chisel-lancet-oncol-2019","kind":"paper","name":"Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial","route":"/key-papers/paper-chisel-lancet-oncol-2019/"}],"trial":[{"id":"stars-rosel","kind":"trial","name":"STARS and ROSEL pooled analysis","route":"/trials/stars-rosel/"}]}}